| Literature DB >> 24381600 |
Rishad R Jivani1, Chhagan N Patel2, Dashrath M Patel2, Nurudin P Jivani1.
Abstract
The present study deals with development of a floating in-situ gel of the narrow absorption window drug baclofen. Sodium alginate-based in-situ gelling systems were prepared by dissolving various concentrations of sodium alginate in deionized water, to which varying concentrations of drug and calcium bicarbonate were added. Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) were used to check the presence of any interaction between the drug and the excipients. A 3(2) full factorial design was used for optimization. The concentrations of sodium alginate (X1) and calcium bicarbonate (X2) were selected as the independent variables. The amount of the drug released after 1 h (Q1) and 10 h (Q10) and the viscosity of the solution were selected as the dependent variables. The gels were studied for their viscosity, in-vitro buoyancy and drug release. Contour plots were drawn for each dependent variable and check-point batches were prepared in order to get desirable release profiles. The drug release profiles were fitted into different kinetic models. The floating lag time and floating time found to be 2 min and 12 h respectively. A decreasing trend in drug release was observed with increasing concentrations of CaCO3. The computed values of Q1 and Q10 for the check-point batch were 25% and 86% respectively, compared to the experimental values of 27.1% and 88.34%. The similarity factor (f 2) for the check-point batch being 80.25 showed that the two dissolution profiles were similar. The drug release from the in-situ gel follows the Higuchi model, which indicates a diffusion-controlled release. A stomach specific in-situ gel of baclofen could be prepared using floating mechanism to increase the residence time of the drug in stomach and thereby increase the absorption.Entities:
Keywords: Baclofen; Floating in-situ gel; Narrow absorption window
Year: 2010 PMID: 24381600 PMCID: PMC3870059
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1FTIR spectrum of baclofen
Figure 2FTIR spectrum of in-situ gelling formulation
Figure 3DSC thermographs: (A) Pure baclofen (B) Sodium alginate (C) Drug-loaded formulations.
In-vitro buoyancy of baclofen formulations
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
| 80 | 60 | 50 | 80 | 60 | 50 | 80 | 60 | 50 |
|
| 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
Design layout for “32” factorial design
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
|
| 1.5% | 0.5% | -1 | -1 | 50.9 ± 1.46 | 99.89 ± 2.12 | 112 ± 8.76 |
|
| 1.5% | 1% | -1 | 0 | 55.45 ± 2.28 | 99.08 ± 1.45 | 134 ± 4.74 |
|
| 1.5% | 1.5% | -1 | 1 | 39.5 ± 2.16 | 93.98 ± 2.77 | 154 ± 8.11 |
|
| 2% | 0.5% | 0 | -1 | 34.5 ± 2.41 | 91.81 ± 3.49 | 225 ± 10.73 |
|
| 2% | 1% | 0 | 0 | 27.7 ± 1.78 | 87.02 ± 4.82 | 236 ± 7.90 |
|
| 2% | 1.5% | 0 | 1 | 33.15 ± 2.09 | 85.29 ± 2.66 | 266 ± 5.53 |
|
| 2.5% | 0.5% | 1 | -1 | 25.9 ± 1.88 | 77.87 ± 2.83 | 295 ± 8.29 |
|
| 2.5% | 1% | 1 | 0 | 20 ± 0.07 | 73.91 ± 3.65 | 330 ± 11.67 |
|
| 2.5% | 1.5% | 1 | 1 | 14.5 ± 0.96 | 63.19 ± 2.00 | 359 ± 14.44 |
X1 is the percentage of sodium alginate, X2 is the percentage of calcium carbonate, Q1 is the percent drug release during the first hour, and Q10 is the percent drug release after 10 h. Viscosity is shown in cps (n = 3). All batches contain 20 mg of baclofen
Summary of regression output of significant factors for measured responses
|
|
| ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| R2 | |
|
| 32.65 | -4.02 | -14.24 | -1.308 | 2.59 | -1.77 | 0.914 |
|
| 88.92 | -4.51 | -12.99 | -1.33 | -3.58 | -2.913 | 0.989 |
|
| 241.1 | 24.5 | 97.33 | 1.83 | -11.66 | 5.5 | 0.998 |
Results of the two-way ANOVA for dependent variables
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
| ||||||
|
| 2 | 100.6 | 50.3 | 1.6 | 0.308 | |
|
| 2 | 1230.3 | 615.1 | 19.63 | 0.009 | |
|
| 4 | 125.32 | 31.3 | |||
|
| 8 | 1456.33 | 182.0 | |||
|
| ||||||
|
| 2 | 126 | 63.0 | 7.714 | 0.04 | |
|
| 2 | 1036.4 | 518.2 | 63.43 | 0.001 | |
|
| 4 | 32.67 | 8.1 | |||
|
| 8 | 1195.13 | 149.3 | |||
|
| ||||||
|
| 2 | 3608 | 1804 | 31.49 | 0.004 | |
|
| 2 | 57114 | 28857 | 498.57 | 0.001 | |
|
| 4 | 229 | 57.27 | |||
|
| 8 | 60952 | 7619 | |||
Q1 is the percent drug release during the first hour, and Q10 is the percent drug release after 10 h. Viscosity is measured in cps. DF is the degree of freedom, SS is the sum of squares and F is the Fischer’s ratio.
Figure 4Contour plots showing the drug release during the first hour (Q1) at different combinations of X1 and X2. The contour lines show the percent drug release at the end of the first hour
Figure 5Contour plots showing the drug release after 10 h (Q10) at different combinations of X1 and X2. The contour lines show the percent drug release at the end of the 10th hour
Figure 6Contour plots showing viscosity at different combinations of X1 and X2. The contour lines show the viscosity
Figure 7Overlapping region of the contour plots of all variables
Figure 8Theoretical and the check-point batch release profile